Elevance Health Inc. Common Stock Q3 2026 Earnings Recap

Elevance raised its 2026 adjusted EPS outlook and set a higher earnings baseline, while projecting at least 12% EPS growth in 2027. Shares fell 1.4%, a broadly flat reaction that tempers the upbeat outlook; the transcript does not identify a specific source of investor disappointment.

Key Takeaways

• 2026 adjusted diluted EPS guidance was raised to at least $29; the company also raised its underlying earnings baseline to at least $26.75, citing better operating results and favorable non-operating items.
• Management expects at least 12% adjusted EPS growth in 2027, driven by Health Benefits margin improvement, Carelon adoption, and operating efficiency.
• Medicaid results were ahead of outlook, primarily due to recent rate actions, and the business is tracking slightly ahead of its prior full-year margin guidance.
• About half of Medicare Advantage members will be in plans rated 4 stars or higher for 2027; management said its plan design and market focus support further margin improvement.
• Carelon’s commercial cancer care engagement program reduced avoidable inpatient admissions by 15%; its Elevate platform identified more than $300 million in anticipated savings this year.